2024
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bagatell R, Park J, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai A, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 413-433. PMID: 39151455, DOI: 10.6004/jnccn.2024.0040.Peer-Reviewed Original ResearchConceptsNCCN GuidelinesNCCN Clinical Practice GuidelinesClinically heterogeneous diseaseExtracranial solid tumorTreatment of neuroblastomaClinical practice guidelinesNeuroblastoma panelRadiation oncologistsNCCN Member InstitutionsSolid tumorsHeterogeneous diseaseConsensus recommendationsPediatric oncologistsNeuroblastomaNCCNGroup of representativesRisk classificationEvidence-basedMultidisciplinary groupPractice guidelinesOncologistsMember institutionsGuidelinesTreatmentTumor
2019
Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma
Imran H, Siddiqui AH, Wilson F, Pashankar F. Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e630-e633. PMID: 31205224, DOI: 10.1097/mph.0000000000001525.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaRecurrent immature teratomaImmature teratomaTeratoma syndromePediatric patientsMainstay of treatmentPostoperative chemotherapyGynecologic oncologistsPediatric oncologistsAdult providersChemotherapyPatientsOncologistsSyndromeTeratomaAdultsTreatmentSurgeryRecurrenceManagementMainstay
2017
Germ Cell Tumors of the Ovary
Matei D, Frazier A, Hurteau J, Pashankar F. Germ Cell Tumors of the Ovary. 2017, 518-532. DOI: 10.1002/9781119196235.ch35.Peer-Reviewed Original ResearchGerm cell tumorsOvarian germ cell tumorsCell tumorsNondysgerminomatous germ cell tumorsPrimitive germ cell tumorsMixed germ cell tumorCornerstone of treatmentYolk sac tumorPrinciples of diagnosisLong-term toxicityQuality of lifeCurrent multidisciplinary approachLonger life expectancyNongestational choriocarcinomaHistological typeSac tumorRare tumorEmbryonal carcinomaMost womenTumorsYoung womenLife expectancyMultidisciplinary approachWomenTreatment
2014
Rituximab for the Treatment of Acute Refractory ITP
Kim SG, Whyte D, Pashankar FD. Rituximab for the Treatment of Acute Refractory ITP. Journal Of Pediatric Hematology/Oncology 2014, 36: e149-e151. PMID: 23669737, DOI: 10.1097/mph.0b013e318292f006.Peer-Reviewed Original ResearchConceptsRefractory immune thrombocytopenic purpuraImmune thrombocytopenic purpuraFirst-line therapyTreatment of ITPAcute immune thrombocytopenic purpuraSecond-line therapySustained remissionIntravenous immunoglobulinIntravenous rituximabEffective regimenImmune globulinAcute settingThrombocytopenic purpuraCombined therapyRituximabMost childrenTherapyClear consensusTreatmentCorticosteroidsRemissionPurpuraRegimenPatientsImmunoglobulin
2012
Management of Thyroid Carcinoma in Children and Young Adults
Rapkin L, Pashankar FD. Management of Thyroid Carcinoma in Children and Young Adults. Journal Of Pediatric Hematology/Oncology 2012, 34: s39-s46. PMID: 22525405, DOI: 10.1097/mph.0b013e31824e37a6.Peer-Reviewed Original ResearchConceptsMedullary thyroid cancerThyroid cancerRadioactive iodineCancers of childhoodSuppression of thyroidPediatric carcinomasAdjuvant benefitNew medicationsSuspicious lesionsThyroid carcinomaBeneficial treatmentCancerAdolescent treatmentPatientsYoung adultsAdult dataWDTCSurgeryCarcinomaTreatmentChildhoodLow thresholdLarge groupMedicationsVandetanib